US 12,427,210 B2
Compounds comprising a fibroblast activation protein ligand and use thereof
Frank Osterkamp, Berlin (DE); Dirk Zboralski, Berlin (DE); Eberhard Schneider, Brandenburg (DE); Christian Haase, Berlin (DE); Matthias Paschke, Berlin (DE); Aileen Höhne, Berlin (DE); Jan Ungewiss, Berlin (DE); Christiane Smerling, Berlin (DE); Ulrich Reineke, Berlin (DE); and Anne Bredenbeck, Berlin (DE)
Assigned to 3B PHARMACEUTICALS GMBH, Berlin (DE)
Appl. No. 17/625,139
Filed by 3B PHARMACEUTICALS GMBH, Berlin (DE)
PCT Filed Jul. 8, 2020, PCT No. PCT/EP2020/069298
§ 371(c)(1), (2) Date Jan. 6, 2022,
PCT Pub. No. WO2021/005125, PCT Pub. Date Jan. 14, 2021.
Claims priority of application No. 19000325 (EP), filed on Jul. 8, 2019; and application No. 19198813 (EP), filed on Sep. 20, 2019.
Prior Publication US 2022/0273831 A1, Sep. 1, 2022
Int. Cl. A61K 51/08 (2006.01); A61K 38/00 (2006.01); C07K 7/08 (2006.01)
CPC A61K 51/088 (2013.01) [C07K 7/08 (2013.01); A61K 38/00 (2013.01)] 55 Claims
 
1. A compound, which is:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, or a solvate thereof; or

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, or a solvate thereof.